Washing COVID-19 Away With a Hypertonic Seawater Nasal Irrigation Solution
SARS-CoV2 Infection
About this trial
This is an interventional other trial for SARS-CoV2 Infection focused on measuring Nasal irrigation, Hypertonic seawater solution, SARS-CoV2, Viral load
Eligibility Criteria
Inclusion Criteria: adult patients hospitalized primarily for COVID-19 pneumonia confirmed SARS-CoV2 infection diagnosed through RT-PCR test of nasopharyngeal samples Exclusion Criteria: patients with confirmed SARS-CoV2 infection who were not primarily admitted for COVID-19 pneumonia patients with use of intranasal sprays for at least two weeks prior to study enrollment sinonasal surgery within 3 months prior to study enrollment patients with sinusitis inability to perform nasopharyngeal wash participation in other trials
Sites / Locations
- University Hospital of Larissa
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Hypertonic seawater group
control group
Patients that will receive nasal irrigations with hypertonic (2.3% NaCl) seawater solution containing brown algae (Undaria pinnatifida) and blue-green algae (Spirulina platensis) as well as essential oils of Eucalyptus globulus and Mentha spicata, and Thymus vulgaris extract (Sinomarin® Plus Algae Cold & Flu Relief, Gerolymatos International SA, Krioneri, Greece)
Patients that will not perform nasal irrigations